Endothelins and Chronic Diabetic Complications
Author Information
Author(s): Subrata Chakrabarti, Zia Ali Khan, Mark Cukiernik, Gen Fukuda, Shali Chen, Suranjana Mukherjee
Primary Institution: The University of Western Ontario
Hypothesis
Alteration of endothelins (ETs) plays a significant role in the pathogenesis of chronic diabetic complications.
Conclusion
Endothelins are implicated in the development of various chronic complications of diabetes, and their antagonism may offer therapeutic benefits.
Supporting Evidence
- Endothelins are altered in various tissues affected by diabetes.
- ET antagonists can prevent changes induced by diabetes in animal models.
- Chronic diabetic complications include retinopathy, nephropathy, neuropathy, and cardiomyopathy.
- Hyperglycemia leads to metabolic changes that affect endothelin levels.
- Endothelins can cause both vasodilation and vasoconstriction depending on their concentration.
- Diabetes-induced changes in endothelin levels may contribute to hypertension.
- Endothelins are involved in the regulation of extracellular matrix protein synthesis.
- Good metabolic control can normalize endothelin levels in diabetic models.
Takeaway
Endothelins are special proteins that can cause problems in people with diabetes, making their health worse. Blocking these proteins might help treat some of these problems.
Methodology
This is a review article discussing various studies on endothelins and their role in diabetic complications.
Limitations
The review is based on existing literature, which may have varying methodologies and results.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website